Subtype
Ovarian Neoplasm
CI-CAN-00001335Explore in graph →
Non-malignant747 active trials5 approved drugs94 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001335Explore in graph →
Clinical trials
3,431 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01540565 | Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | Jul 23, 2019 | clinicaltrials |
| NCT01523678 | Weekly Paclitaxel/Carboplatin With Neupogen in Gynaecological Cancers | completed | Phase 2 | 108 | Belgian Gynaecological Oncology GroupOTHER | 1 | Jul 10, 2019 | clinicaltrials |
| NCT01432145 | A Clinical Trial in Patients With Breast Cancer Susceptibility Gene (BRCA) Defective Tumours(6MP) | completed | Phase 2 | 74 | University of OxfordOTHER | 1 | Jul 9, 2019 | clinicaltrials |
| NCT01567891 | CT Antigen TCR-redirected T Cells for Ovarian Cancer. | completed | Phase 1 / Phase 2 | 9 | AdaptimmuneINDUSTRY | 1 | Jun 27, 2019 | clinicaltrials |
| NCT00826150 | Phase 1/2a Study of DTA-H19 in Advanced Stage Ovarian Cancer | completed | Phase 1 / Phase 2 | 14 | Anchiano Therapeutics Israel Ltd.INDUSTRY | 1 | Jun 13, 2019 | clinicaltrials |
| NCT01610869 | Low Dose Cyclophosphamide +/-- Nintedanib in Advanced Ovarian Cancer(METRO-BIBF) | completed | Phase 2 | 117 | University College, LondonOTHER | 1 | May 29, 2019 | clinicaltrials |
| NCT01556841 | The Activity of TroVax® Versus Placebo in Relapsed Asymptomatic Ovarian Cancer(TRIOC) | completed | Phase 2 | 94 | University College, LondonOTHER | 1 | May 9, 2019 | clinicaltrials |
| NCT00088413 | PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer | completed | Phase 1 / Phase 2 | 51 | National Cancer Institute (NCI)NIH | 1 | Apr 16, 2019 | clinicaltrials |
| NCT00407758 | Enzastaurin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer | completed | Phase 2 | 28 | Gynecologic Oncology GroupNETWORK | 1 | Mar 20, 2019 | clinicaltrials |
| NCT02591095 | A Study of ABT-263 as Single Agent in Women With Platinum Resistant/Refractory Recurrent Ovarian Cancer(MONAVI-1) | completed | Phase 2 | 47 | Centre Francois BaclesseOTHER | 1 | Mar 19, 2019 | clinicaltrials |
| NCT01381861 | Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma | completed | Phase 2 | 23 | Tracon Pharmaceuticals Inc.INDUSTRY | 1 | Mar 5, 2019 | clinicaltrials |
| NCT00436501 | VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | completed | Phase 1 / Phase 2 | 58 | National Cancer Institute (NCI)NIH | 1 | Feb 26, 2019 | clinicaltrials |
| NCT01010126 | Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer | completed | Phase 2 | 252 | National Cancer Institute (NCI)NIH | 2 | Jan 25, 2019 | clinicaltrials |
| NCT00939809 | A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 31 | Gynecologic Oncology GroupNETWORK | 1 | Jan 15, 2019 | clinicaltrials |
| NCT03804866 | NGR-hTNF in Combination With an Anthracycline in Platinum-resistant Ovarian Cancer (NGR018) | completed | Phase 2 | 14 | AGC Biologics S.p.A.INDUSTRY | 1 | Jan 15, 2019 | clinicaltrials |
| NCT03042702 | A Phase 2 Study of Kevetrin in Subjects With Ovarian Cancer | completed | Phase 2 | 2 | Innovation Pharmaceuticals, Inc.INDUSTRY | 1 | Dec 27, 2018 | clinicaltrials |
| NCT01936363 | Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer | completed | Phase 2 | 65 | EMD SeronoINDUSTRY | 7 | Dec 12, 2018 | clinicaltrials |
| NCT01669798 | BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer | completed | Phase 2 | 32 | AA SecordOTHER | 1 | Oct 16, 2018 | clinicaltrials |
| NCT00030706 | Ixabepilone in Treating Patients With Relapsed and/or Refractory Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer | completed | Phase 2 | — | Montefiore Medical CenterOTHER | 1 | Sep 28, 2018 | clinicaltrials |
| NCT00484432 | Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Advanced or Metastatic Ovarian Cancer | completed | Phase 2 | 37 | AGC Biologics S.p.A.INDUSTRY | 1 | Sep 27, 2018 | clinicaltrials |
| NCT01358071 | Phase II Study of NGR-hTNF in Combination With Doxorubicin in Platinum-resistant Ovarian Cancer(NGR018) | completed | Phase 2 | 119 | AGC Biologics S.p.A.INDUSTRY | 2 | Sep 27, 2018 | clinicaltrials |
| NCT00281632 | A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer | completed | Phase 2 | 35 | GlaxoSmithKlineINDUSTRY | 3 | Sep 17, 2018 | clinicaltrials |
| NCT00856180 | Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian Malignancies | completed | Phase 2 | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 10, 2018 | clinicaltrials |
| NCT00278343 | Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer | completed | Phase 2 | 74 | National Cancer Institute (NCI)NIH | 2 | Aug 29, 2018 | clinicaltrials |
| NCT00467051 | Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors | completed | Phase 2 | 20 | Children's Oncology GroupNETWORK | 4 | Aug 29, 2018 | clinicaltrials |
| NCT00768144 | Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma | completed | Phase 2 | 36 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 24, 2018 | clinicaltrials |
| NCT00301756 | Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors | completed | Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Aug 20, 2018 | clinicaltrials |
| NCT01154452 | Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma | completed | Phase 1 / Phase 2 | 78 | National Cancer Institute (NCI)NIH | 1 | Aug 15, 2018 | clinicaltrials |
| NCT02107950 | Phase II Study DCVAC/OvCa Plus Carboplatin Gemcitabine Relapsed Platinum (Pt)-Sensitive Epithelial Ovarian Carcinoma | completed | Phase 2 | 71 | SOTIO a.s.INDUSTRY | 3 | Aug 15, 2018 | clinicaltrials |
| NCT00230542 | Carboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian Cancer | completed | Phase 2 | 44 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 13, 2018 | clinicaltrials |
| NCT00002943 | Carboplatin, Etoposide, Cyclophosphamide, and Autologous Bone Marrow Transplantation in Patients With Relapsed or Refractory Cancer | completed | Phase 2 | 11 | Wake Forest University Health SciencesOTHER | 1 | Aug 10, 2018 | clinicaltrials |
| NCT00494442 | Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer(ICEBERG 2) | completed | Phase 2 | 58 | AstraZenecaINDUSTRY | 5 | Aug 1, 2018 | clinicaltrials |
| NCT00520013 | Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors | completed | Phase 2 | 60 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 27, 2018 | clinicaltrials |
| NCT00114166 | Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 81 | Gynecologic Oncology GroupNETWORK | 1 | Jul 24, 2018 | clinicaltrials |
| NCT00699907 | Effect of Flutamide on Biomarkers in Blood and Tissue Samples From Patients at High Risk of Ovarian Cancer | completed | Phase 2 | 127 | University of ArizonaOTHER | 1 | Jul 24, 2018 | clinicaltrials |
| NCT00867503 | Open Trial of Bendamustine Hydrochloride in Women With Advanced Ovarian Cancer | completed | Phase 2 | 10 | University of ArizonaOTHER | 1 | Jul 24, 2018 | clinicaltrials |
| NCT00459290 | Mifepristone in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | 24 | Gynecologic Oncology GroupNETWORK | 1 | Jul 18, 2018 | clinicaltrials |
| NCT00569673 | Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer | completed | Phase 2 | 71 | Gynecologic Oncology GroupNETWORK | 1 | Jul 18, 2018 | clinicaltrials |
| NCT01824615 | Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma | completed | Phase 2 | 30 | Cathay General HospitalOTHER | 1 | Jul 18, 2018 | clinicaltrials |
| NCT01553539 | Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery | completed | Phase 2 | 20 | Wake Forest University Health SciencesOTHER | 1 | Jul 5, 2018 | clinicaltrials |
| NCT01652079 | CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer | completed | Phase 2 | 63 | Massachusetts General HospitalOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT02948075 | Safety and Efficacy of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy | completed | Phase 2 | 31 | NewVac LLCINDUSTRY | 1 | Jun 27, 2018 | clinicaltrials |
| NCT00228319 | Treatment of Newly Diagnosed Ovarian Cancer With Antioxidants | completed | Phase 1 / Phase 2 | 27 | Jeanne Drisko, MD, CNS, FACNOTHER | 1 | Jun 19, 2018 | clinicaltrials |
| NCT01867086 | Salvage Ovarian FANG™ Vaccine + Carboplatinum | completed | Phase 2 | 1 | Gradalis, Inc.INDUSTRY | 1 | Jun 19, 2018 | clinicaltrials |
| NCT02340611 | A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib | completed | Phase 2 | 4 | University Health Network, TorontoOTHER | 1 | Jun 12, 2018 | clinicaltrials |
| NCT01113957 | A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer | completed | Phase 2 | 168 | AbbVie (prior sponsor, Abbott)INDUSTRY | 8 | Jun 6, 2018 | clinicaltrials |
| NCT01091428 | Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer | completed | Phase 2 | 191 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Jun 4, 2018 | clinicaltrials |
| NCT01764802 | Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer | completed | Phase 2 | 100 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | May 30, 2018 | clinicaltrials |
| NCT00428610 | A Study of Chemotherapy Treatment for Patients With Ovarian Cancer | completed | Phase 2 | 103 | Eli Lilly and CompanyINDUSTRY | 3 | Apr 19, 2018 | clinicaltrials |
| NCT01644825 | Weekly Paclitaxel With or Without Pazopanib in Platinum Resistant or Refractory Ovarian Cancer(MITO-11) | completed | Phase 2 | 72 | National Cancer Institute, NaplesOTHER | 1 | Apr 9, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Jul 23, 2019source: clinicaltrials